ASCO 23 (American Society of Clinical Oncology) Annual Meeting in Chicago showcased a plethora of cutting-edge trials and research. Upper gastrointestinal cancers such as gastric, pancreatic and hepatobiliary are usually relegated to the backstage, but this year, several exciting and potentially practice-changing studies (not without their limitations).

We explore a new PD-1Toripalimab in gastric and gastroesophageal cancer, liposomal irinotecan in NALIRIFOX versus gemcitabine/abraxane in metastatic pancreatic cancer, neoadjuvant FOLFIRINOX in pancreatic cancer and the new HER2 kid on the block zanidatamab, a bispecific monoclonal antibody.

Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.

Studies:

Toripalimab + SOX study: https://meetings.asco.org/abstracts-presentations/219777

NAPOLI-3 study: https://meetings.asco.org/abstracts-presentations/222090

NORPACT-1 study: https://meetings.asco.org/abstracts-presentations/219426

HORIZON-BTC-01 study: https://meetings.asco.org/abstracts-presentations/219904

Special Mention (not included in the episode)

DIPLOMA Study: https://meetings.asco.org/abstracts-presentations/218312

Lauren Classification: https://open.acast.com/shows/62d20dbcffef490011c8df4b/episodes

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

*SPECIAL EPISODE ALERT*

Every year, Josh and Mike cross their fingers and pray to Father Conference-Leave that they can make the pilgrimage to one of the two central sites of Oncology: Madrid for ESMO or Chicago for ASCO. Unfortunately, to this point, Father Conference-Leave has not delivered, and 2023 is no different. However, the cold and wind will not stop our intrepid hosts from parsing the avalanche of potentially practice-changing studies, agents and professional development about to descend on the Windy City

So, consider today's episode what our American listeners would call an "appetizer," a taste of what may be coming from the American Society of Clinical Oncology Annual Meeting for 2023. This will be followed by a string of episodes breaking the aforementioned avalanche down and examining it with a fine tooth comb, with one episode dedicated to each tumour stream. So, do not adjust your set, as there will be a huge amount of Oncology content coming your way. As well as some helpful hints about North American geography.

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023, but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Peripheral neuropathy is a common toxicity of multiple anticancer agents used to treat and cure cancer, including platinum, taxanes and vinca alkaloids chemotherapy. These chemotherapy classes are as ubiquitous for cancer treatment as the sun is to plant photosynthesis. This week on OncoSnacks, Michael and Josh investigate what to do when a patient has peripheral neuropathy and examine existing evidence for prevention, treatment and duration of this sequelae.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

It is always nice to be able to say the phrase: "This cancer has an excellent prognosis." That is the case with endometrial cancer, which for the majority of sufferers, can be cured and carries an excellent survival. However, there are cases that unfortunately present late, and for these patients, the outlook is significantly more grim.

Some oncologists have little experience treating advanced endometrial cancer; for those listeners, this episode is specifically for you! In our 40th episode, Josh will discuss the foundations of endometrial cancer treatment, a topic that is vital but very boring, much like Josh himself. Michael will discuss the new frontier of immunotherapy in dMMR endometrial cancer, something that is transformative and very exciting but also unfortunately irrelevant to the majority of patients, much like Michael.

Links to studies discussed in this episode (subscription may be required):

GOG0209: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676887/

RUBY: https://www.nejm.org/doi/full/10.1056/NEJMoa2216334

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

COSA President-elect (Clinical Oncology Society Australia), Professor Sabe Sabesan, is the oncologist and doctor we all dreamed of being when starting our medical training. This is a story of adversity, compassion and drive without compromise. Sabe's global journey has taken him to some of the remotest places on earth, with each inflection point creating new challenges and opportunities. We discuss advocacy, the rollout of teletrials to improve equitable access, redefining system issues with the lasagna model and looking after the little guy. Michael and Josh are the OFTIM team and are humbled to share Sabe's story, a tale many of us can only aspire to achieve.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

On Oncology for the Inquisitive Mind, we like to focus on cancer and available treatment options. However, every oncologist is at his or her best when working hand-in-hand with other specialities. In this, our seventh episode of OncoSnacks, Michael and Josh interview Dr Mark Nolan, a non-invasive cardiologist with a special interest in anti-cancer treatment-induced cardiotoxicity. Mark provides an engaging, comprehensive overview of the diagnosis and management of cardiotoxicity, with a particular focus on the two usual culprits: anthracyclines and anti-HER2 agents. A must listen for anyone who has been confronted with a left ventricular ejection fraction (LVEF) of 40%...I mean 30%... oh, now it's 20%...

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

Adenoid Cystic Carcinoma (ACC) is a rare cancer commonly found in the head and neck region, arising from glandular salivary tissue. Like many orphan cancers, effective treatments in the metastatic setting are needed desperately. The 5-year survival rate is 80% and declines over time. In this special subseries: Rare Cancer Snapshots, Michael and Josh pour over the evidence for ACC, pathophysiology and the treatment paradigm to date.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Lutetium PSMA (Lutetium-177), theranostic medicine and future advances in prostate cancer are coming to an oncology centre near you faster than you can say "novel drug development" and "progression-free survival". This week Michael and Josh conclude their epic prostate cancer trilogy by exploring theranostic medicine and radioactive drug development while looking at the past of the cytotoxic world and the role of cabazitaxel. To ensure we keep your attention, six trials are discussed today, and a shout out to TheraP, the Australian phase 2 trial from the land down under.

Links to studies discussed in this episode (subscription may be required):

Tropic trial: https://www.thelancet.com/article/S0140-6736(10)61389-X/fulltext

CARD trial: https://www.nejm.org/doi/full/10.1056/nejmoa1911206

Corn et al: https://pubmed.ncbi.nlm.nih.gov/31515154/

TheraP: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00237-3/fulltext

Vision: https://www.nejm.org/doi/full/10.1056/nejmoa2107322

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Every feast needs a palate cleanser. Every great work of theatre needs an intermission. Every sports event needs a half-time show. In this way, Oncology for the Inquisitive Mind is no different to Hamilton or the Super Bowl. Here, we provide a little deviation from our ongoing Prostate Cancer Saga to interview Dr Jenny Liu, Oncologist and early drug development (EDD) researcher extraordinaire. Our discussions range from her slightly unusual path to oncology, her previous research and how it is still making waves in the oncological community, and her other great passion: mentorship. Suppose you are interested in Phase One trials, mentorship opportunities (especially in Australia), or simply enjoy Josh dredging up dirt on highly accomplished clinicians. In that case, this is the episode for you!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In the second episode of our prostate-cancer series, we investigate the inevitability of castration resistance: the biochemical, radiological and clinical progression of prostate cancer despite the best efforts of the heroic MDT. While this space will likely change in the coming years, with many novel anti-androgen agents displaying efficacy in the HSPC space, the current standards of care for patients include docetaxel and the dynamic duo of abiraterone + prednisolone and enzalutamide. These latter two agents are frequently used in the first line when a patient cannot or is unlikely to tolerate docetaxel chemotherapy.

However, there can only be one Lord of the Anti-Androgens, and today Josh and Michael will reveal their preferred agent. Listen on to find out which, and please, contain your excitement.

Links to studies discussed in this episode (subscription may be required):

1. PREVAIL: https://www.nejm.org/doi/full/10.1056/nejmoa1405095
2. COU-AA-302: https://www.nejm.org/doi/full/10.1056/nejmoa1209096
3. TAX-327 (cameo only): https://www.nejm.org/doi/full/10.1056/nejmoa040720

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.